Dexcom Inc Stock Performance
| DXCM Stock | USD 78.10 0.16 0.21% |
On a scale of 0 to 100, DexCom holds a performance score of 7. The firm shows a Beta (market volatility) of 0.23, which means not very significant fluctuations relative to the market. As returns on the market increase, DexCom's returns are expected to increase less than the market. However, during the bear market, the loss of holding DexCom is expected to be smaller as well. Please check DexCom's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether DexCom's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in DexCom Inc are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, DexCom displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 643.3 M |
DexCom |
DexCom Relative Risk vs. Return Landscape
If you would invest 6,934 in DexCom Inc on August 30, 2024 and sell it today you would earn a total of 876.00 from holding DexCom Inc or generate 12.63% return on investment over 90 days. DexCom Inc is currently generating 0.2104% in daily expected returns and assumes 2.1019% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than DexCom, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DexCom Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DexCom's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DexCom Inc, and traders can use it to determine the average amount a DexCom's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1001
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | DXCM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.1 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average DexCom is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DexCom by adding it to a well-diversified portfolio.
DexCom Fundamentals Growth
DexCom Stock prices reflect investors' perceptions of the future prospects and financial health of DexCom, and DexCom fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DexCom Stock performance.
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 30.5 B | ||||
| Shares Outstanding | 390.6 M | ||||
| Price To Earning | 245.31 X | ||||
| Price To Book | 15.36 X | ||||
| Price To Sales | 7.70 X | ||||
| Revenue | 3.62 B | ||||
| EBITDA | 916.7 M | ||||
| Cash And Equivalents | 2.37 B | ||||
| Cash Per Share | 6.14 X | ||||
| Total Debt | 2.59 B | ||||
| Debt To Equity | 1.17 % | ||||
| Book Value Per Share | 5.07 X | ||||
| Cash Flow From Operations | 748.5 M | ||||
| Earnings Per Share | 1.65 X | ||||
| Total Asset | 6.26 B | ||||
| Retained Earnings | 1.02 B | ||||
| Current Asset | 231.3 M | ||||
| Current Liabilities | 66.9 M | ||||
About DexCom Performance
By examining DexCom's fundamental ratios, stakeholders can obtain critical insights into DexCom's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that DexCom is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people.Things to note about DexCom Inc performance evaluation
Checking the ongoing alerts about DexCom for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DexCom Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 97.0% of the company shares are held by institutions such as insurance companies |
- Analyzing DexCom's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DexCom's stock is overvalued or undervalued compared to its peers.
- Examining DexCom's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DexCom's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DexCom's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DexCom's stock. These opinions can provide insight into DexCom's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.